大规模依赖性与药物筛选揭示伴1q染色体异常的多发性骨髓瘤治疗脆弱性
研究利用大规模依赖性与药物筛选,系统刻画伴1q获得或扩增的多发性骨髓瘤的治疗脆弱性,发现其对MCL1和PI3K抑制剂敏感性增高;单细胞RNA测序显示1q+亚克隆MCL1与PI3K通路水平更高,分离等基因克隆证实1q臂水平获得对上述抑制剂敏感性增加;两种抑制剂具协同作用,机制为细胞静止效应。
要点
- 伴1q+的多发性骨髓瘤对MCL1和PI3K抑制剂表现出增高的敏感性。
- 单细胞RNA测序显示同一患者肿瘤中1q+亚克隆的MCL1与PI3K通路水平更高。
- MCL1与PI3K抑制剂在伴1q+的多发性骨髓瘤中具协同作用,机制为细胞静止效应。
核心结论
- 伴1q+的多发性骨髓瘤可能对MCL1和PI3K抑制剂呈现增强的敏感性,有望以较低剂量使用而不牺牲疗效,从而可能加速针对伴1q+多发性骨髓瘤患者的靶向治疗开发。
研究设计与样本
- 研究采用大规模依赖性与药物筛选,并结合单细胞RNA测序及分离等基因克隆的方法,系统刻画伴1q+多发性骨髓瘤的治疗脆弱性。
主要发现
- 大规模依赖性与药物筛选显示伴1q+的多发性骨髓瘤对MCL1和PI3K抑制剂敏感性增高。
- 单细胞RNA测序比较同一患者肿瘤内伴与不伴1q+的亚克隆,显示1q+与更高水平的MCL1及PI3K通路相关。
- 分离对部分1q臂具有不同拷贝数谱的等基因克隆后,观察到臂水平获得对MCL1和PI3K抑制剂的敏感性增加。
- MCL1与PI3K抑制剂在伴1q+的多发性骨髓瘤中显示协同作用,机制解析揭示为细胞静止效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.
引用
- Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, et al. Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q. Blood. 2025. PMID: 40073369. doi:10.1182/blood.2024025102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。